No association between the COMT Val158Met polymorphism and the long-term clinical response in obsessive–compulsive disorder in the Japanese population
Hidehiro Umehara
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorCorresponding Author
Shusuke Numata
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Correspondence to: S. Numata, Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-8-15 Kuramoto-cho Tokushima 770-8503, Japan. Tel: 81-886-33-7130, Fax: 81-886-33-7131, E-mail: [email protected]Search for more papers by this authorAtsushi Tajima
Department of Bioinformatics and Genomics, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan
Department of Human Genetics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorMakoto Kinoshita
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorShutaro Nakaaki
Laboratory of Aging, Behavior and Cognition, Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorIssei Imoto
Department of Human Genetics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorSatsuki Sumitani
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorTetsuro Ohmori
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorHidehiro Umehara
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorCorresponding Author
Shusuke Numata
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Correspondence to: S. Numata, Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-8-15 Kuramoto-cho Tokushima 770-8503, Japan. Tel: 81-886-33-7130, Fax: 81-886-33-7131, E-mail: [email protected]Search for more papers by this authorAtsushi Tajima
Department of Bioinformatics and Genomics, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan
Department of Human Genetics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorMakoto Kinoshita
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorShutaro Nakaaki
Laboratory of Aging, Behavior and Cognition, Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorIssei Imoto
Department of Human Genetics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorSatsuki Sumitani
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorTetsuro Ohmori
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Search for more papers by this authorAbstract
Objective
Catechol-O-methyltransferase (COMT) is an enzyme that participates in the metabolic inactivation of dopamine and norepinephrine, and the Met allele of the COMT Val158Met polymorphism is associated with lower enzymatic activity. The purpose of the present study was to investigate whether this functional variant is associated with obsessive–compulsive disorder (OCD) and the clinical responses in OCD.
Methods
We first performed a case-control association study between the COMT Val158Met polymorphism and OCD (171 cases and 944 controls). Then, we examined the association between this polymorphism and the clinical responses in 91 of the OCD patients.
Results
Our study did not find a significant association between the Met allele and OCD risk or between the Met allele and clinical responses (p > 0.05).
Conclusion
The present case-control/pharmacogenetic study did not provide clear evidence that the COMT Val158Met polymorphism is a predictor of OCD or of OCD patients' clinical responses. Copyright © 2015 John Wiley & Sons, Ltd.
References
- Arumugham SS, Reddy JYC. 2013. Augmentation strategies in obsessive–compulsive disorder. Expert Rev Neurother 13: 187–202; quiz 203. Informa HealthcareLondon.
- Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. 2006. A systematic review: antipsychotic augmentation with treatment refractory obsessive–compulsive disorder. Mol Psychiatry 11: 622–32.
- Chen J, Lipska BK, Halim N, et al. 2004. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75: 807–21.
- Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HGM. 2004. Low level of dopaminergic D2 receptor binding in obsessive–compulsive disorder. Biol Psychiatry 55: 1041–5.
- Denys D, Van Nieuwerburgh F, Deforce D, Westenberg H. 2006. Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive–compulsive disorder in males. Eur Neuropsychopharmacol 16: 446–50.
- Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HGM. 2007. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive–compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 68: 747–53.
- Erdal ME, Tot S, Yazici K, et al. 2003. Lack of association of catechol-O-methyltransferase gene polymorphism in obsessive–compulsive disorder. Depress Anxiety 18: 41–5.
- Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L. 2001. Clinical predictors of drug response in obsessive–compulsive disorder. J Clin Psychopharmacol 21: 488–92.
- Hsieh H-J, Lue K-H, Tsai H-C, Lee C-C, Chen S-Y, Kao P-F. 2014. l-3,4-Dihydroxy-6-[F-18]fluorophenylalanine positron emission tomography demonstrating dopaminergic system abnormality in the brains of obsessive–compulsive disorder patients. Psychiatry Clin Neurosci. DOI: 10.1111/pcn.12139.
- Karayiorgou M, Altemus M, Galke BL, et al. 1997. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive–compulsive disorder. Proc Natl Acad Sci U S A 94: 4572–5.
- Katerberg, H, Cath, DC, Denys, D, et al. 2010. The role of the COMT Val(158)Met polymorphism in the phenotypic expression of obsessive–compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 153B: 167–76.
- Kim C-H, Jeong J-W, Kim EJ, et al. 2011. Clinical predictors of drug response in patients with obsessive–compulsive disorder. Clin Psychopharmacol Neurosci 9: 23–8.
-
Mattheisen M,
Samuels JF,
Wang Y, et al. 2014. Genome-wide association study in obsessive–compulsive disorder: results from the OCGAS. Mol Psychiatry. DOI: 10.1038/mp.2014.43. Macmillan Publishers Limited.
10.1038/mp.2014.43 Google Scholar
- Meira-Lima I, Shavitt RG, Miguita K, Ikenaga E, Miguel EC, Vallada H. 2004. Association analysis of the catechol-o-methyltransferase (COMT), serotonin transporter (5-HTT) and serotonin 2A receptor (5HT2A) gene polymorphisms with obsessive–compulsive disorder. Genes Brain Behav 3: 75–9.
- Miguita K, Cordeiro Q, Shavitt RG, Miguel EC, Vallada H. 2011. Association study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment. Arq Neuropsiquiatr 69: 283–7.
- Nicolini H, Arnold P, Nestadt G, Lanzagorta N, Kennedy JL. 2009. Overview of genetics and obsessive–compulsive disorder. Psychiatry Res 170: 7–14.
- Niehaus DJ, Kinnear C, Corfield V, et al. 2001. Association between a catechol-o-methyltransferase polymorphism and obsessive–compulsive disorder in the Afrikaner population. J Affect Disord 65: 61–65.
- Ohara K, Nagai M, Suzuki Y, Ochiai M, Ohara K. 1998. No association between anxiety disorders and catechol-O-methyltransferase polymorphism. Psychiatry Res 80: 145–148.
- Olver JS, O'Keefe G, Jones GR, et al. 2010. Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive–compulsive disorder. Psychiatry Res 183: 85–8. Elsevier B.V.
- Olver JS, O'Keefe G, Jones GR, et al. 2009. Dopamine D1 receptor binding in the striatum of patients with obsessive–compulsive disorder. J Affect Disord 114: 321–6.
- Pallanti S, Hollander E, Bienstock C, et al. 2002. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5: 181–191. Cambridge University Press.
- Pauls DL. 2010. The genetics of obsessive–compulsive disorder: a review. Dialogues Clin Neurosci 12: 149–63.
- Perani D, Garibotto V, Gorini A, et al. 2008. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive–compulsive disorder. Neuroimage 42: 306–14.
- Pooley EC, Fineberg N, Harrison PJ. 2007. The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive–compulsive disorder in men: case-control study and meta-analysis. Mol Psychiatry 12: 556–61.
- Poyurovsky M, Michaelovsky E, Frisch A, et al. 2005. COMT Val158Met polymorphism in schizophrenia with obsessive–compulsive disorder: a case-control study. Neurosci Lett 389: 21–4.
- Ruscio AM, Stein DJ, Chiu WT, Kessler RC. 2010. The epidemiology of obsessive–compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15: 53–63.
- Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. 2008. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive–compulsive disorder (OCD). Cochrane Database Syst Rev CD001765.
- Stewart SE, Yu D, Scharf JM, et al. 2013. Genome-wide association study of obsessive–compulsive disorder. Mol Psychiatry 18: 788–98.
-
Taylor S. 2012. Molecular genetics of obsessive–compulsive disorder: a comprehensive meta-analysis of genetic association studies. Mol Psychiatry. DOI: 10.1038/mp.2012.76. Nature Publishing Group.
10.1038/mp.2012.76 Google Scholar
- Tükel, R, Gürvit, H, Öztürk, N, et al. 2013. COMT Val158Met polymorphism and executive functions in obsessive–compulsive disorder. J Neuropsychiatry Clin Neurosci 25: 214–21. American Psychiatric Association.
- Vulink NCC, Westenberg HGM, van Nieuwerburgh F, et al. 2012. Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive–compulsive disorder. Int J Psychiatry Clin Pract 16: 277–83.
